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987presentation compared with healthy volunteers
(1,253  63 ms vs. 1,188  16 ms, p ¼ 0.004), and this
improved signiﬁcantly (1,196  29 ms) at follow-up
(p ¼ 0.01) (Figure 1A). The acute changes were driven
by both the T1 values measured from acutely
dysfunctional segments (T1 ¼ 1,279  86 ms, p ¼
0.03 vs. healthy controls) but also by the segments
with normal wall motion in the acute study (1,226 
49 ms, p ¼ 0.02 vs. healthy controls). At follow-up,
the T1 relaxation times signiﬁcantly improved
(1,177  42 ms) compared with the acute study in
the nondysfunctional segments (p ¼ 0.008), but this
improvement only showed a trend in the
previously dysfunctional myocardium (p ¼ 0.05),
which remained signiﬁcantly abnormal compared
with healthy controls (T1 ¼ 1,224  40 ms, p ¼ 0.013
vs. healthy controls), implying that a certain degree
of myocardial edema remains present until at least
this stage.
A profound decrease in resting cardiac energetic
status was seen during the acute tako-tsubo phase
compared with healthy volunteers (phosphocreatine/
adenosine triphosphate [PCr/ATP] ratio 1.1  0.39 vs.
1.9  0.43, p << 0.0001). The PCr/ATP ratio increased
to 1.5  0.48 at 4 months follow-up (p ¼ 0.018
compared with initial presentation) but remained
signiﬁcantly reduced compared with normal healthy
volunteers (p ¼ 0.02) (Figure 1B).
We demonstrate severe global edema associated
with profound cardiac energetic impairment with
incomplete resolution of both at 4 months. These
observations contribute to the understanding of TTC
pathophysiology.
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Structural Heart Disease:
All That Glitters Is Not GoldWe read with interest the article by O’Neill et al. (1)
describing the utility of 3-dimensional printing (3DP)
in caval valve implantation. Theirs is an interesting
extension of earlier work by Kim et al. (2). Both
groups provide glimpses into the true incremental
value of printing-graspable 3D models in structural
heart disease (SHD), namely, the ability to optimize
device selection through direct physical interaction.
Many hurdles must be crossed, however, before
3DP can become mainstream technology in SHD.
Sengupta et al. (3) raised the issue of cost-
effectiveness. Beyond that, several technical factors
must ﬁrst be standardized and validated.
First, the fundamentals of 3DP must be well under-
stood by the clinician. This includes an understanding
of details such as the following: 1) primary data
acquisition; 2) model extraction (image processing); 3)
printer speciﬁcations; and 4) material properties.
Attention to such detail will reveal technical discrep-
ancies that could inﬂuence clinical results. One author
provided a proof-of-concept report testing the cost-
effectiveness and anatomic accuracy of 3DP (4);
however, larger scale studies are needed.
Second, the role of image processing is critical and
yet underappreciated. As in all clinical imaging, the
balance between signal and noise must be maintained.
Similar precaution applies to imaging-derived 3DP.
Kim et al. (2) describe multistep model extraction
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988that includes “shrink-wrapping” deformation, noise
averaging, and outer/inner surface creation using
viewing windows. Although these steps are essential
to model extraction, each step steers us further away
from source data. At what point does the anatomic
model become an aesthetic sculpture?
This is illustrated by our own 3DP experience. We
derived a 3D model of an aortic root with anomalous
coronaries from a cardiac computed tomography
angiography image using a Siemens Sensation
64-slice scanner (Siemens Medical Solutions Inc.,
Malvern, Pennsylvania) and printed it on a Stratasys
Dimension Elite station (Stratasys Ltd., Minneapolis,
Minnesota) using acrylonitrile butadiene styrene
plastic (Figure 1). Our model was not manually edited.
Figure 1A shows a fracture due to fragility at a
previous stent site (arrow). Since the contrast-
endovascular interface is nonuniform, variability in
extraction results in “holes” in the model
(Figure 1B). Image processing can “ﬁx” these holes
and offset fragility; however, this diverts us away
from true anatomy.
Lastly, the elasticity of print materials must be
validated against that of cardiac tissues. Without
this, physical interaction with models is unreliable.
The material properties of the IVC model of O’Neill
et al. (1) are unclear. In this case, printing with stiff
plastic, rubber, or metal could potentially alter
device selection. Recently, a mitral valve was
printed with pliable materials (5). As elucidatedof an Aortic Root With Anomalous Right Coronary Artery Origin
emonstrated by a fracture at the site of a previous stent (arrow). (B)
ons (“holes”) visible in the 3D model resulting from model extraction
uniform contrast-endovascular interface. 3D ¼ 3-dimensional.in this work, using materials mimicking tissue
properties could lead to applications in ex vivo
device testing and training. In our own aortic root
model (Figure 1B), for example, printing with a
pliable material could enable preliminary test
interactions with transcatheter valves.
In conclusion, we share the enthusiasm for the
potential of 3DP in SHD. However, multiple technical
aspects must be ﬁrst standardized and validated
before meaningful clinical strides can be made with
3DP in the clinical domain.Moses Mathur, MD, MSc*
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Heart Disease: All That Glitters Is Not GoldWe thank Dr. Mathur and colleagues for their interest
in our experience with computer-aided design and
3D printing (CAD3DP) in structural heart disease
periprocedural planning (1). We agree that in the
eventual technological investment in personalized
heart valves, there will need to be standardization
of 3D printing for health care delivery. The focus,
however, should not be on the 3D print itself, but
the integration of advanced multidetector slice
computed tomography (CT) image reconstruction
with CAD3DP for successful periprocedural planning.
